Study Name:
IMPALA2
Purpose of Study:
To discover whether molgramostim (inhaled GM-CSF) is safe to take and can help to reduce the symptoms of (autoimmune pulmonary alveolar proteinosis ) aPAP.
Study Dates:
May 3, 2021 - June 30, 2024
Study Location:
Nationwide
Lead Institution:
Cincinnati Children's Hospital Medical Center
Funding Source:
Savara Inc.
Sponsors:
Savara Inc.
Contact:
Michele Rhee
512-614-1848
michele.rhee@savarapharma.com
ClinicalTrails.gov Identifier:
NCT04544293
